TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15499886

Group type: EXPERIMENTAL
Intervention: Explicit rule‐based instruction approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basal‐reader activity‐based approach
Number of subjects: 40
Study: 8953628

Group type: EXPERIMENTAL
Intervention: Neural networks using clinical and pathological data
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Neural networks with additional specialized markers
Number of subjects: 81
Study: 1672802

Group type: EXPERIMENTAL
Intervention: Higher dose of vecuronium (2.5 X ED95)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lower dose of vecuronium (1 X ED95)
Number of subjects: 32
Study: 7316031

Group type: EXPERIMENTAL
Intervention: Open (Penrose) drainage
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Closed sump drainage
Number of subjects: 122

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 122
Study: 31992407

Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT) - 2 sessions with interim phone contact
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) - 6 sessions
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sleep Education Control - 6 sessions
Number of subjects: 150
Study: 31075059

Group type: EXPERIMENTAL
Intervention: Paced respiration
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control (music listening)
Number of subjects: 161
Study: 28558147

Group type: EXPERIMENTAL
Intervention: SinuBand FP
Number of subjects: 30

Group type: COMPARATOR
Intervention: SinuBand (without FP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Merocel (standard nasal pack)
Number of subjects: 30
Study: 26466681

Group type: EXPERIMENTAL
Intervention: Education messages for schistosomiasis prevention + pre-treatment snack (2013)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Education messages for schistosomiasis prevention (2013)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Education messages for schistosomiasis prevention + pre-treatment snack (2014)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Education messages for schistosomiasis prevention (2014)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prevalence of S. mansoni infection (2013)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prevalence of S. mansoni infection (2014)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Geometric mean intensity of S. mansoni infection (2013)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Geometric mean intensity of S. mansoni infection (2014)
Number of subjects: 12
Study: 22420871

Group type: EXPERIMENTAL
Intervention: SRP plus 1.2% SMV
Number of subjects: 38

Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 38
Study: 21164500

Group type: EXPERIMENTAL
Intervention: Upper tertile for previous dietary adherence
Number of subjects: 116
Study: 19763023

Group type: EXPERIMENTAL
Intervention: Combined photodynamic therapy (PDT) and sub-Tenon's capsule injection of 20 mg triamcinolone acetonide (TA)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Combined PDT and TA
Number of subjects: 117

Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 117
Study: 17124018

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 13819

Group type: COMPARATOR
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819
Study: 15582343

Group type: EXPERIMENTAL
Intervention: Leaflet with pictograms
Number of subjects: 90

Group type: COMPARATOR
Intervention: Leaflet with plain text
Number of subjects: 90
Study: 11265775

Group type: EXPERIMENTAL
Intervention: MUC1‐mannan fusion protein (M‐FP) administered at doses of 1 to 300 microg, given intramuscularly in trial 1 and intraperitoneally in trial 2, with immunizations at weekly intervals (weeks 1 to 3) and repeated in weeks 7 to 9. Cyclophosphamide was given on weeks 1 and 4.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cyclophosphamide (to increase cellular immunity)
Number of subjects: 41
Study: 9427901

Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8279757

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Primary radiotherapy
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Low-SPF tumors
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: High-SPF nonresponders
Number of subjects: 184
Study: 3334236

Group type: EXPERIMENTAL
Intervention: Short plantar splint
Number of subjects: 300

Group type: COMPARATOR
Intervention: Spica strapping
Number of subjects: 300
Study: 30095791

Group type: EXPERIMENTAL
Intervention: Weekly teriparatide administration starting at 1 week postoperatively
Number of subjects: 66

Group type: COMPARATOR
Intervention: No teriparatide administration (control group)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Weekly teriparatide administration
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Preoperative anterior slippage of the cranial vertebra next to fusion segment < 2 mm
Number of subjects: 66
Study: 30094335

Group type: EXPERIMENTAL
Intervention: Tyrosine administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26687339

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg, once a night) plus rosuvastatin (10mg, once a night)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Rosuvastatin alone (10mg, once a night)
Number of subjects: 106
Study: 24661107

Group type: EXPERIMENTAL
Intervention: GTR plus LLLT (1064 nm, 100 mW, energy density of 4 J/cm²)
Number of subjects: 13

Group type: COMPARATOR
Intervention: GTR alone
Number of subjects: 13
Study: 22079604

Group type: EXPERIMENTAL
Intervention: Music and local anesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Local anesthesia alone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 20590479

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) intervention, administered for five 1-minute bouts per session, 3 days per week, for 6 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (CON), asked not to commence any form of physical training
Number of subjects: 37
Study: 18399868

Group type: EXPERIMENTAL
Intervention: MTB12 Ag
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MTB12 and 38-kDa Ag
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTB12 Ag plus 38-kDa Ag
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTB12 Ag plus 30-kDa Ag
Number of subjects: 0
Study: 15807812

Group type: EXPERIMENTAL
Intervention: Physical irritation during work in the dispatch department
Number of subjects: 71
Study: 12437705

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture with needles placed at the Shen Men, Thalamus, Tranquiliser and Master Cerebral Points on the right ear
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study: 10494774

Group type: EXPERIMENTAL
Intervention: Regular low to moderate intensity physical activity
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-intervention reference group
Number of subjects: 132
Study: 8766893

Group type: EXPERIMENTAL
Intervention: 0.18 to 1.1 g per day of long‐chain polyunsaturated omega‐3 fatty acids (fish oil capsules)
Number of subjects: 20
Study: 1672530

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (300,000 IU daily for 12 months)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 283
Study: 6126871

Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: chlorpheniramine maleate
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 31595600

Group type: EXPERIMENTAL
Intervention: 120 mg galcanezumab
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 240 mg galcanezumab
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 29749316

Group type: EXPERIMENTAL
Intervention: Group spiritual intervention (10 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 28108936

Group type: EXPERIMENTAL
Intervention: GMCB (group-mediated cognitive behavioral) physical activity intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: TRAD (traditional exercise therapy)
Number of subjects: 80
Study: 25395013

Group type: EXPERIMENTAL
Intervention: Breast milk expression education and support intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 25090937

Group type: EXPERIMENTAL
Intervention: 2D speckle-tracking echocardiography
Number of subjects: 42
Study: 23101492

Group type: EXPERIMENTAL
Intervention: Artesunate 2mg/kg/day for three days
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Artesunate 4mg/kg/day for three days
Number of subjects: 166

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 166
Study: 19100282

Group type: EXPERIMENTAL
Intervention: GP+ES+P group (General Practitioner + Exercise Scientist + Pedometer)
Number of subjects: 136

Group type: COMPARATOR
Intervention: GP group (General Practitioner only)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: GP+ES group (General Practitioner + Exercise Scientist)
Number of subjects: 136
Study: 17446980

Group type: EXPERIMENTAL
Intervention: 3-hour baseline intervention
Number of subjects: 3406

Group type: EXPERIMENTAL
Intervention: 3-hour baseline intervention plus two booster sessions
Number of subjects: 3406

Group type: COMPARATOR
Intervention: Assessments only (control group)
Number of subjects: 3406
Study: 15811058

Group type: EXPERIMENTAL
Intervention: Placement of periodontal dressing (Vocopac) with removal after 7-8 days (group 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Placement of periodontal dressing (Vocopac) with removal after 3-4 days (group 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group without periodontal dressing
Number of subjects: 36
Study: 12459350

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (HT) - 4 months of goserelin (3.6 mg every 4 weeks) and flutamide (250 mg t.i.d.) before and during RT
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (HT)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 456
Study: 10334230

Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical nasal decongestant (oxymetazoline hydrochloride, 0.2 mg per nostril)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of decongestant and ENDS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (without ENDS)
Number of subjects: 20
Study: 7503003

Group type: EXPERIMENTAL
Intervention: felodipine ER
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: combined felodipine/simvastatin therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study: 2021284

Group type: EXPERIMENTAL
Intervention: 360 mg/day of Diltiazem
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 60 mg/day of Nifedipine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 180 mg/day of Diltiazem with 30 mg/day of Nifedipine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of Diltiazem and Nifedipine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diltiazem alone
Number of subjects: 18
Study: 7051796

Group type: EXPERIMENTAL
Intervention: Hydralazine (200 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hydralazine and Placebo
Number of subjects: 32
Study: 28976841

Group type: EXPERIMENTAL
Intervention: Repair (n=35, 20 AM, 15 RC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Replacement (n=43, 21 AM, 22 RC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Positive control (n=71, 49 AM, 22 RC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Negative control (n=18, 10 AM, 8 RC)
Number of subjects: 34
Study: 27855441

Group type: EXPERIMENTAL
Intervention: HPV screening (Safety arm)
Number of subjects: 12278

Group type: COMPARATOR
Intervention: Liquid Based Cytology (LBC) screening (Control arm)
Number of subjects: 12278

Group type: EXPERIMENTAL
Intervention: LBC screening at 24 months (Safety arm)
Number of subjects: 12278

Group type: COMPARATOR
Intervention: LBC screening at 24 months (Control arm)
Number of subjects: 12278
Study: 24445291

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (400, 10,000, or 40,000 IU/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Combined higher-dose groups (10,000 and 40,000 IU/d)
Number of subjects: 63
Study: 23559286

Group type: EXPERIMENTAL
Intervention: High Intensity Intervals (HIT, n = 12)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Resistance (R, n = 8)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Combined group (HIT + R, n = 10)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (CG, n = 13)
Number of subjects: 43
Study: 20017599

Group type: EXPERIMENTAL
Intervention: Combination of azacitidine and cytarabine
Number of subjects: 34
Study: 18997910

Group type: EXPERIMENTAL
Intervention: Power brush with wireless display
Number of subjects: 61

Group type: COMPARATOR
Intervention: Power brush alone
Number of subjects: 61
Study: 16436127

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative HBV DNA levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Log HBV DNA testing at week 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HBV DNA at baseline and decrease in HBV DNA from baseline to week 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HBeAg levels
Number of subjects: 0
Study: 14552410

Group type: EXPERIMENTAL
Intervention: Earnings-supplement policies
Number of subjects: 2
Study: 11933488

Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing (Aquacel)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alginate dressing (Sorbsan)
Number of subjects: 100
Study: 8690551

Group type: EXPERIMENTAL
Intervention: Laser-assisted angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard angioplasty
Number of subjects: 0
Study: 1818389

Group type: EXPERIMENTAL
Intervention: Oral artesunate (1200, 600, 650 mg total doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (480 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shorter courses of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hematological effects
Number of subjects: 0
Study: 6355321

Group type: EXPERIMENTAL
Intervention: HuIFN‐alpha 2, 8.4 X 10(6) U/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30040525

Group type: EXPERIMENTAL
Intervention: Immediate teaching group (parents taught smartphone otoscopy and cerumen removal at the first visit)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Delayed teaching group (parents received teaching intervention after 1 week's independent use)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Immediate teaching group
Number of subjects: 699

Group type: COMPARATOR
Intervention: Delayed teaching group
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Parents' experience with smartphone otoscopy
Number of subjects: 699
Study: 27594054

Group type: EXPERIMENTAL
Intervention: Bilingual modality (ASL with English closed captioning)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Monolingual modality (English text)
Number of subjects: 150
Study: 25716702

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dexsol®, Rosemont Pharmaceuticals Ltd) 6 mg daily for 5 days, started within 24 hours of admission.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 0
Study: 24680232

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wait List Control (WLC)
Number of subjects: 34
Study: 23067919

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1900
Study: 19324916

Group type: EXPERIMENTAL
Intervention: T3 (0.8 microg kg(‐1) bolus; 0.113 microg kg(‐1) h(‐1) infusion)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1000 mg bolus)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both T3 and methylprednisolone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17531887

Group type: EXPERIMENTAL
Intervention: High-dose NaFeEDTA (56 mg/kg)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Low-dose NaFeEDTA (28 mg/kg)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Electrolytic iron (56 mg/kg)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Unfortified whole maize flour (control group)
Number of subjects: 516
Study: 15383086

Group type: EXPERIMENTAL
Intervention: Pulsed tissue Doppler imaging during dobutamine stress testing
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dobutamine stress testing
Number of subjects: 26
Study: 11468502

Group type: EXPERIMENTAL
Intervention: Providing health information to residents of Boise, ID
Number of subjects: 5909

Group type: COMPARATOR
Intervention: Control cities (not specified)
Number of subjects: 5909
Study: 9710167

Group type: EXPERIMENTAL
Intervention: Walkabout Orthosis (WO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocentric Reciprocal Gait Orthosis (IRGO)
Number of subjects: 10
Study: 7527406

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (E2) 10 mg E2 valerate
Number of subjects: 2
Study: 2921874

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epinephrine (222 ng/kg per min)
Number of subjects: 12
Study: 30395144

Group type: EXPERIMENTAL
Intervention: Symptom monitoring intervention
Number of subjects: 150
Study: 28888275

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic optimization (MAP 85-100 mm Hg, SVO2 65%-75%)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard care strategy (MAP 65 mm Hg)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic optimization
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard care strategy
Number of subjects: 112
Study: 25459097

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate-emtricitabine (TDF-FTC)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study: 23497119

Group type: EXPERIMENTAL
Intervention: Job-specific workers' health surveillance (WHS)
Number of subjects: 899
Study: 22254717

Group type: EXPERIMENTAL
Intervention: WCDMA RF exposure for 30 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 20
Study: 18849613

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16618907

Group type: EXPERIMENTAL
Intervention: Combination of surgery, radiation therapy, and chemotherapy (cisplatin and paclitaxel) along with intraoperative radiation therapy
Number of subjects: 32
Study: 15131760

Group type: EXPERIMENTAL
Intervention: 14-mg transdermal nicotine patch
Number of subjects: 34
Study: 11900420

Group type: EXPERIMENTAL
Intervention: Panels with sensor lines and compatible linkages
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Panels with sensor lines and incompatible linkages
Number of subjects: 96

Group type: COMPARATOR
Intervention: Compatible panels without sensor lines
Number of subjects: 96

Group type: COMPARATOR
Intervention: Incompatible panels without sensor lines
Number of subjects: 96
Study: 10087976

Group type: EXPERIMENTAL
Intervention: Single 4-hour infusion of 1500 mg Clodronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional 2-hour infusion of 300 mg Clodronate
Number of subjects: 0
Study: 8092591

Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil and midazolam (IN‐SM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular meperidine, promethazine, and chlorpromazine (IM‐MPC)
Number of subjects: 0
Study: 3134266

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms q.i.d.)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg q.i.d.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 90
Study: 30239519

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (ice chips held in mouth during chemotherapy infusion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (sodium bicarbonate mouthwash postchemotherapy)
Number of subjects: 80
Study: 28096255

Group type: EXPERIMENTAL
Intervention: Rehabilitation plus usual care
Number of subjects: 326

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 326
Study: 26496205

Group type: EXPERIMENTAL
Intervention: Real TENS (50 Hz, 15 min/day for 5 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 36
Study: 23645097

Group type: EXPERIMENTAL
Intervention: Telephone Assessment Battery (TAB)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Traditional in-person Cognitive Assessment Battery
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Telephone Interview for Cognitive Status (TICS)
Number of subjects: 1548
Study: 21546387

Group type: EXPERIMENTAL
Intervention: eSET
Number of subjects: 177

Group type: COMPARATOR
Intervention: DET
Number of subjects: 177
Study: 18990201

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299 (Lp299)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 50
Study: 17144916

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32